Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
Add more filters










Publication year range
1.
Protein Expr Purif ; 219: 106480, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38588871

ABSTRACT

Mpox is a zoonotic disease that was once endemic in Africa countries caused by mpox virus. However, cases recently have been confirmed in many non-endemic countries outside of Africa. The rapidly increasing number of confirmed mpox cases poses a threat to the international community. In-depth studies of key viral factors are urgently needed, which will inform the design of multiple antiviral agents. Mpox virus A41L gene encodes a secreted protein, A41, that is nonessential for viral replication, but could affect the host response to infection via interacting with chemokines. Here, mpox virus A41 protein was expressed in Sf9 cells, and purified by affinity chromatography followed by gel filtration. Surface plasmon resonance spectroscopy showed that purified A41 binds a certain human chemokine CXCL8 with the equilibrium dissociation constant (KD) being 1.22 × 10-6 M. The crystal structure of mpox virus A41 protein was solved at 1.92 Å. Structural analysis and comparison revealed that mpox virus A41 protein adopts a characteristic ß-sheet topology, showing minor differences with that of vaccinia virus. These preliminary structural and functional studies of A41 protein from mpox virus will help us better understand its role in chemokine subversion, and contributing to the knowledge to viral chemokine binding proteins.


Subject(s)
Viral Proteins , Humans , Viral Proteins/genetics , Viral Proteins/chemistry , Viral Proteins/metabolism , Viral Proteins/biosynthesis , Viral Proteins/isolation & purification , Crystallography, X-Ray , Animals , Interleukin-8/genetics , Interleukin-8/chemistry , Interleukin-8/metabolism , Gene Expression , Sf9 Cells , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism , Recombinant Proteins/biosynthesis , Yatapoxvirus/genetics , Yatapoxvirus/chemistry , Yatapoxvirus/metabolism
2.
J Cancer Res Ther ; 16(4): 708-712, 2020.
Article in English | MEDLINE | ID: mdl-32930107

ABSTRACT

Insufficiency of standard cancer therapeutic agents and a high degree of toxicity associated with chemotherapy and radiotherapy have created a dearth of therapeutic options for metastatic cancers. Oncolytic viruses (OVs) are an emerging therapeutic option for the treatment of various human cancers. Several OVs, including poxviruses, are currently in preclinical and clinical studies and have shown to be effective in treating metastatic cancer types. Tanapoxvirus (TANV), a member of the Poxviridae family, is being developed as an OV for different human cancers due to its desirable safety and efficacy features. TANV causes a mild self-limiting febrile disease in humans, does not spread human to human, and its large genome makes it a relatively safer OV for use in humans. TANV is relatively well characterized at both molecular and clinical levels. Some of the TANV-encoded proteins that are a part of the virus' immune evasion strategy are also characterized. TANV replicates considerably slower than vaccinia virus. TANV has been shown to replicate in different human cancer cells in vitro and regresses human tumors in a nude mouse model. TANV is currently being developed as a therapeutic option for several human cancers including breast cancer, ovarian cancer, colorectal cancer, pancreatic cancer, retinoblastoma, and melanoma. This review provides a comprehensive summary from the discovery to the development of TANV as an OV candidate for a wide array of human cancers.


Subject(s)
Neoplasms/therapy , Oncolytic Virotherapy/methods , Yatapoxvirus/physiology , Animals , Disease Models, Animal , Humans , Neoplasms/immunology , Neoplasms/pathology , Neoplasms/virology , Yatapoxvirus/genetics , Yatapoxvirus/immunology
3.
Curr Cancer Drug Targets ; 18(6): 577-591, 2018.
Article in English | MEDLINE | ID: mdl-28669340

ABSTRACT

BACKGROUND: Oncolytic viruses (OVs), which preferentially infect cancer cells and induce host anti-tumor immune responses, have emerged as an effective melanoma therapy. Tanapoxvirus (TANV), which possesses a large genome and causes mild self-limiting disease in humans, is potentially an ideal OV candidate. Interleukin-2 (IL-2), a T-cell growth factor, plays a critical role in activating T cells, natural killer (NK) cells and macrophages in both the innate and adaptive immune system. OBJECTIVE: We aimed to develop a recombinant TANV expressing mouse IL-2 (TANVΔ66R/mIL- 2), replacing the viral thymidine kinase (TK) gene (66R) with the mouse (m) mIL-2 transgene resulting in TANVΔ66R/mIL-2. METHODS: Human melanoma tumors were induced in female athymic nude mice by injecting SKMEL- 3 cells subcutaneously. Mice were treated with an intratumoral injection of viruses when the tumor volumes reached 45 ± 4.5 mm3. RESULTS: In cell culture, expression of IL-2 attenuated virus replication of not only TANVΔ66R/ mIL-2, but also TANVGFP. It was demonstrated that IL-2 inhibited virus replication through intracellular components and without activating the interferon-signaling pathway. Introduction of mIL-2 into TANV remarkably increased its anti-tumor activity, resulting in a more significant regression than with wild-type (wt) TANV and TANVΔ66R. Histopathological studies showed that extensive cell degeneration with a significantly increased peri-tumor accumulation of mononuclear cells in the tumors treated with TANVΔ66R/mIL-2, compared to wtTANV or TANVΔ66R. CONCLUSION: We conclude that TANVΔ66R/mIL-2 is potentially therapeutic for human melanomas in the absence of T cells, and IL-2 expression resulted in an overall increase of therapeutic efficacy.


Subject(s)
Interleukin-2/metabolism , Melanoma/therapy , Oncolytic Virotherapy/methods , T-Lymphocytes/immunology , Yatapoxvirus/genetics , Animals , Apoptosis , Cell Proliferation , Female , Humans , Interleukin-2/administration & dosage , Interleukin-2/genetics , Melanoma/immunology , Melanoma/pathology , Melanoma/virology , Mice , Mice, Nude , Tumor Cells, Cultured , Virus Replication , Xenograft Model Antitumor Assays
4.
Med Oncol ; 34(6): 112, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28466296

ABSTRACT

Human triple negative breast cancer (TNBC) is an aggressive disease, associated with a high rate of recurrence and metastasis. Current therapeutics for TNBC are limited, highly toxic and show inconsistent efficacy due to a high degree of intra-tumoral and inter-tumoral heterogeneity. Oncolytic viruses (OVs) are an emerging treatment option for cancers. Several OVs are currently under investigation in preclinical and clinical settings. Here, we examine the oncolytic potential of two tanapoxvirus (TPV) recombinants expressing mouse monocyte chemoattractant protein (mMCP)-1 [also known as mCCL2] and mouse interleukin (mIL)-2, in human TNBC, in vitro and in vivo. Both wild-type (wt) TPV and TPV recombinants demonstrated efficient replicability in human TNBC cells and killed cancer cell efficiently in a dose-dependent manner in vitro. TPV/∆66R/mCCL2 and TPV/∆66R/mIL-2 expressing mCCL2 and mIL-2, respectively, suppressed the growth of MDA-MB-231 tumor xenografts in nude mice significantly, as compared to the mock-injected tumors. Histological analysis of tumors showed areas of viable tumor cells, necrotic foci and immune cell accumulation in virus-treated tumors. Moreover, TPV/∆66R/mIL-2-treated tumors showed a deep infiltration of mononuclear immune cells into the tumor capsule and focal cell death in tumors. In conclusion, TPV recombinants expressing mCCL2 and mIL-2 showed a significant therapeutic effect in MDA-MB-231 tumor xenografts, in nude mice through induction of potent antitumor immune responses. Considering the oncolytic potency of armed oncolytic TPV recombinants expressing mCCL2 and mIL-2 in an experimental nude mouse model, these viruses merit further investigation as alternative treatment options for human breast cancer.


Subject(s)
Chemokine CCL2/metabolism , Immunotherapy/methods , Interleukin-2/metabolism , Oncolytic Viruses/genetics , Triple Negative Breast Neoplasms/metabolism , Yatapoxvirus/genetics , Animals , Aotidae , Cell Line , Chemokine CCL2/genetics , Chemokine CCL2/immunology , Humans , Interleukin-2/genetics , Interleukin-2/immunology , Male , Mice , Mice, Nude , Oncolytic Viruses/metabolism , Triple Negative Breast Neoplasms/genetics , Triple Negative Breast Neoplasms/immunology , Xenograft Model Antitumor Assays , Yatapoxvirus/metabolism
5.
Virus Genes ; 53(3): 477-482, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28188458

ABSTRACT

Oncolytic viruses (OVs) have emerged as a promising approach for melanoma treatment by causing tumor lysis and inducing immuno-modulatory activities. Tanapoxvirus (TPV), which causes a mild self-limiting disease in humans and contains a large DNA genome, appears as a promising OV candidate. TPV recombinants were generated with the thymidine kinase/66R gene deletion (TPVΔ66R), the 15L gene deletion (TPVΔ15L), or with both the 15L and 66R gene ablation (TPVΔ15LΔ66R). Our previous studies have shown that treatment of TPVΔ15L resulted in significant tumor regression in xenotransplanted human melanoma in nude mice. Here, we demonstrate that an anti-viral activity identified as interferon-λ1 (IFN-λ1) was secreted in a remarkably higher quantity from human lung fibroblast WI-38 and melanoma SK-MEL-3 cells infected with TPVΔ15L. Furthermore, we show that IFN-λ1 exhibits a more pronounced anti-proliferative effect in melanoma cells than IFN-α and IFN-ß in vitro. Additional experiments strongly suggest that TPVΔ15L kills melanoma cells partially through inducing IFN-λ1. Taken together, our results demonstrate the immuno-modulatory activities associated with TPVΔ15L and suggest further exploration of TPVΔ15L as a melanoma virotherapy.


Subject(s)
Cell Proliferation , Cytokines/metabolism , Melanoma/therapy , Melanoma/virology , Viral Proteins/metabolism , Yatapoxvirus/genetics , Animals , Antiviral Agents/pharmacology , Cell Line, Tumor , Fibroblasts/immunology , Fibroblasts/virology , Gene Deletion , Genetic Vectors , Interferon-alpha , Interferon-beta , Lung/virology , Melanoma/immunology , Melanoma/pathology , Mice , Mice, Nude , Neuregulins/genetics , Oncolytic Virotherapy/methods , Oncolytic Viruses/genetics , Sequence Deletion , Thymidine Kinase/genetics , Viral Proteins/genetics , Virus Replication
6.
Virus Genes ; 53(1): 52-62, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27738905

ABSTRACT

Neuregulin (NRG), an epidermal growth factor is known to promote the growth of various cell types, including human melanoma cells through ErbB family of tyrosine kinases receptors. Tanapoxvirus (TPV)-encoded protein TPV-15L, a functional mimic of NRG, also acts through ErbB receptors. Here, we show that the TPV-15L protein promotes melanoma proliferation. TPV recombinant generated by deleting the 15L gene (TPVΔ15L) showed replication ability similar to that of wild-type TPV (wtTPV) in owl monkey kidney cells, human lung fibroblast (WI-38) cells, and human melanoma (SK-MEL-3) cells. However, a TPV recombinant with both 15L and the thymidine kinase (TK) gene 66R ablated (TPVΔ15LΔ66R) replicated less efficiently compared to TPVΔ15L and the parental virus. TPVΔ15L exhibited more robust tumor regression in the melanoma-bearing nude mice compared to other TPV recombinants. Our results indicate that deletion of TPV-15L gene product which facilitates the growth of human melanoma cells can be an effective strategy to enhance the oncolytic potential of TPV for the treatment of melanoma.


Subject(s)
Melanoma/pathology , Neuregulins/genetics , Oncolytic Virotherapy , Oncolytic Viruses/genetics , Sequence Deletion , Viral Proteins/genetics , Yatapoxvirus/genetics , Animals , Apoptosis/genetics , Cell Line , Cell Proliferation , Disease Models, Animal , Genetic Vectors/genetics , Humans , Male , Melanoma/metabolism , Melanoma/therapy , Mice , Mice, Nude , Oncolytic Virotherapy/methods , Tumor Burden , Virus Replication , Xenograft Model Antitumor Assays
7.
J Exp Clin Cancer Res ; 34: 19, 2015 Feb 19.
Article in English | MEDLINE | ID: mdl-25887490

ABSTRACT

Colorectal cancers are significant causes of morbidity and mortality and existing therapies often perform poorly for individuals afflicted with advanced disease. Oncolytic virotherapy is an emerging therapeutic modality with great promise for addressing this medical need. Herein we describe the in vivo testing of recombinant variants of the tanapoxvirus (TPV). Recombinant viruses were made ablated for either the 66R gene (encoding a thymidine kinase), the 2L gene (encoding a TNF-binding protein), or both. Some of the recombinants were armed to express mouse chemotactic protein 1 (mCCL2/mMCP-1), mouse granulocyte-monocyte colony stimulating factor (mGM-CSF), or bacterial flagellin (FliC). Tumors were induced in athymic nude mice by implantation of HCT 116 cells and subsequently treated by a single intratumoral injection of one of the recombinant TPVs. Histological examination showed a common neoplastic cell type and a range of immune cell infiltration, necrosis, and tumor cell organization. Significant regression was seen in tumors treated with virus TPV/Δ2L/Δ66R/fliC, and to a lesser extent the recombinants TPV/Δ2L and TPV/Δ66R. Our results suggest that oncolytic recombinants of the TPV armed with activators of the innate immune response may be effective virotherapeutic agents for colorectal cancers in humans and should be explored further to fully realize their potential.


Subject(s)
Colorectal Neoplasms/pathology , Flagellin/genetics , Gene Expression , Genetic Vectors/genetics , Oncolytic Virotherapy , Oncolytic Viruses/genetics , Yatapoxvirus/genetics , Animals , Cell Line, Tumor , Colorectal Neoplasms/therapy , Disease Models, Animal , Genetic Therapy , Genetic Vectors/administration & dosage , Humans , Male , Mice , Transduction, Genetic , Transgenes , Xenograft Model Antitumor Assays
8.
PLoS Pathog ; 8(8): e1002876, 2012.
Article in English | MEDLINE | ID: mdl-22927815

ABSTRACT

Interleukin 18 (IL18) is a cytokine that plays an important role in inflammation as well as host defense against microbes. Mammals encode a soluble inhibitor of IL18 termed IL18 binding protein (IL18BP) that modulates IL18 activity through a negative feedback mechanism. Many poxviruses encode homologous IL18BPs, which contribute to virulence. Previous structural and functional studies on IL18 and IL18BPs revealed an essential binding hot spot involving a lysine on IL18 and two aromatic residues on IL18BPs. The aromatic residues are conserved among the very diverse mammalian and poxviruses IL18BPs with the notable exception of yatapoxvirus IL18BPs, which lack a critical phenylalanine residue. To understand the mechanism by which yatapoxvirus IL18BPs neutralize IL18, we solved the crystal structure of the Yaba-Like Disease Virus (YLDV) IL18BP and IL18 complex at 1.75 Šresolution. YLDV-IL18BP forms a disulfide bonded homo-dimer engaging IL18 in a 2∶2 stoichiometry, in contrast to the 1∶1 complex of ectromelia virus (ECTV) IL18BP and IL18. Disruption of the dimer interface resulted in a functional monomer, however with a 3-fold decrease in binding affinity. The overall architecture of the YLDV-IL18BP:IL18 complex is similar to that observed in the ECTV-IL18BP:IL18 complex, despite lacking the critical lysine-phenylalanine interaction. Through structural and mutagenesis studies, contact residues that are unique to the YLDV-IL18BP:IL18 binding interface were identified, including Q67, P116 of YLDV-IL18BP and Y1, S105 and D110 of IL18. Overall, our studies show that YLDV-IL18BP is unique among the diverse family of mammalian and poxvirus IL-18BPs in that it uses a bivalent binding mode and a unique set of interacting residues for binding IL18. However, despite this extensive divergence, YLDV-IL18BP binds to the same surface of IL18 used by other IL18BPs, suggesting that all IL18BPs use a conserved inhibitory mechanism by blocking a putative receptor-binding site on IL18.


Subject(s)
Intercellular Signaling Peptides and Proteins/chemistry , Interleukin-18/chemistry , Protein Multimerization , Viral Proteins/chemistry , Yatapoxvirus/chemistry , Amino Acid Substitution , Cell Line , Crystallography, X-Ray , Humans , Intercellular Signaling Peptides and Proteins/genetics , Intercellular Signaling Peptides and Proteins/metabolism , Interleukin-18/genetics , Interleukin-18/metabolism , Mutagenesis , Mutation, Missense , Poxviridae Infections/genetics , Poxviridae Infections/metabolism , Protein Structure, Quaternary , Protein Structure, Tertiary , Viral Proteins/genetics , Viral Proteins/metabolism , Yatapoxvirus/genetics , Yatapoxvirus/metabolism
9.
Virology ; 386(2): 462-8, 2009 Apr 10.
Article in English | MEDLINE | ID: mdl-19232662

ABSTRACT

Tanapox virus (TPV) encodes and expresses a secreted TNF-binding protein, TPV-2L or gp38, that displays inhibitory properties against TNF from diverse mammalian species, including human, monkey, canine and rabbit. TPV-2L also has sequence similarity with the MHC-class I heavy chain and interacts differently with human TNF as compared to the known cellular TNF receptors or any of the known virus-encoded TNF receptor homologs derived from many poxviruses. In order to determine the TNF binding region in TPV-2L, various TPV-2L C-terminal truncations and internal deletions were created and the muteins were expressed using recombinant baculovirus vectors. C-terminal deletions from TPV-2L resulted in reduced binding affinity for human TNF and specific mutants of TNF that discriminate between TNF-R1 and TNF-R2. However, deletion of C-terminal 42 amino acid residues totally abolished the binding of human TNF and its mutants. Removal of any of the predicted internal domains resulted in a mutant TPV-2L protein incapable of binding to human TNF. Deletion of C-terminal residues also affected the ability of TPV-2L to block TNF-induced cellular cytotoxicity. In addition to TNF, TPV-2L can also form complexes with human beta2-microglobulin to form a novel macromolecular complex. In summary, the TPV-2L protein is a bona fide MHC-1 heavy chain family member that binds and inhibits human TNF in a fashion very distinct from other known poxvirus-encoded TNF inhibitors, and also can form a novel complex with the human MHC-1 light chain, beta2-microglobulin.


Subject(s)
Tumor Necrosis Factor-alpha/metabolism , Viral Proteins/metabolism , Yatapoxvirus/metabolism , beta 2-Microglobulin/metabolism , Animals , Baculoviridae/genetics , Binding Sites , Cell Line , Humans , Mice , Protein Binding , Receptors, Tumor Necrosis Factor/metabolism , Sequence Deletion , Viral Proteins/genetics , Yatapoxvirus/genetics
10.
Virology ; 368(1): 32-40, 2007 Nov 10.
Article in English | MEDLINE | ID: mdl-17632198

ABSTRACT

Tanapox virus (TPV) belongs to the genus Yatapoxvirus and causes a relatively benign zoonotic disease in man, with symptoms that resemble a mild version of human monkeypox. In order to investigate the underlying mechanisms of TPV pathogenesis, the tropism and replication characteristics of TPV were examined in a variety of primary human cells. A GFP expressing TPV (TPV-GFP) was constructed and used to infect primary human dermal fibroblasts (pHDFs) and peripheral blood mononuclear cells (PBMCs), both of which are believed to be major in vivo targets of poxvirus infection. pHDFs fully supported productive replication and cell-cell spread of TPV-GFP. However, induction of cell cycle arrest in pHDFs by contact mediated inhibition or rapamycin treatment eliminated the ability of TPV to fully stimulate cell cycle progression and dramatically reduced viral replication. TPV-GFP-infected human PBMCs were screened for permissiveness by FACS analysis. CD14+ cells (monocytes) were the primary cellular target for TPV infection. A small proportion of CD3+ cells (T cells) were positive for GFP expression, yet TPV was not able to replicate and spread in cultured peripheral blood lymphocytes, regardless of their state of activation. Primary human monocytes, however, demonstrated robust TPV replication, yet these cells no longer supported replication of TPV once they differentiated into macrophages. This unique ex vivo tropism of TPV gives key insights into the basis for the self-limiting pathogenicity of TPV in man.


Subject(s)
Fibroblasts/virology , Monocytes/virology , Yatapoxvirus/physiology , CD3 Complex/analysis , Cells, Cultured , Genes, Reporter , Green Fluorescent Proteins/biosynthesis , Green Fluorescent Proteins/genetics , Humans , Lipopolysaccharide Receptors/analysis , T-Lymphocytes/virology , Virus Replication/physiology , Yatapoxvirus/genetics , Yatapoxvirus/growth & development
11.
Virus Res ; 129(1): 11-25, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17574698

ABSTRACT

Members of the genus Yatapoxvirus, which include Tanapox virus (TPV) and Yaba monkey tumor virus, infect primates including humans. Two strains of TPV isolated 50 years apart from patients infected from the equatorial region of Africa have been sequenced. The original isolate from a human case in the Tana River Valley, Kenya, in 1957 (TPV-Kenya) and an isolate from an infected traveler in the Republic of Congo in 2004 (TPV-RoC). Although isolated 50 years apart the genomes were highly conserved. The genomes differed at only 35 of 144,565 nucleotide positions (99.98% identical). We predict that TPV-RoC encodes 155 ORFs, however a single transversion (at nucleotide 10241) in TPV-Kenya resulted in the coding capacity for two predicted ORFs (11.1L and 11.2L) in comparison to a single ORF (11L) in TPV-RoC. The genomes of TPV are A+T rich (73%) and 96% of the sequence encodes predicted ORFs. Comparative genomic analysis identified several features shared with other chordopoxviruses. A conserved sequence within the terminal inverted repeat region that is also present in the other members of the Yatapoxviruses as well as members of the Capripoxviruses, Swinepox virus and an unclassified Deerpox virus suggests the existence of a conserved near-terminal sequence secondary structure. Two previously unidentified gene families were annotated that are represented by ORF TPV28L, which matched homologues in certain other chordopoxviruses, and TPV42.5L, which is highly conserved among currently reported chordopoxvirus sequences.


Subject(s)
DNA, Viral/genetics , Genome, Viral , Poxviridae Infections/virology , Tumor Virus Infections/virology , Yatapoxvirus/genetics , Africa , Amino Acid Sequence , Humans , Molecular Sequence Data , Open Reading Frames , Sequence Alignment , Sequence Homology
12.
J Gen Virol ; 87(Pt 4): 809-816, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16528029

ABSTRACT

Yaba-like disease virus (YLDV) gene 7L encodes a seven-transmembrane G protein-coupled receptor with 53 % amino acid identity to human CC chemokine receptor 8 (CCR8). Initial characterization of 7L showed that this 56 kDa cell-surface glycoprotein binds human CCL1 with high affinity (Kd=0.6 nM) and induces signal transduction by activation of heterotrimeric G proteins and downstream protein kinases. Further characterization of YLDV 7L is presented here and shows that murine CC chemokines can induce G-protein activation via the 7L receptor, despite having a low binding affinity for this receptor. In addition, when expressed by recombinant vaccinia virus (VACV), YLDV 7L was found on the outer envelope of VACV extracellular enveloped virus. The contribution of 7L to poxvirus pathogenesis was investigated by infection of mice with a recombinant VACV expressing 7L (vDeltaB8R-7L) and was compared with the outcome of infection by parental and revertant control viruses. In both intranasal and intradermal models, expression of 7L caused attenuation of VACV. The role of this protein in viral virulence is discussed.


Subject(s)
Chemokines, CC/metabolism , Receptors, Chemokine/chemistry , Receptors, Virus , Vaccinia virus/metabolism , Yatapoxvirus/pathogenicity , Administration, Intranasal , Animals , Cell Line , Humans , Injections, Intradermal , Mice , Mice, Inbred BALB C , Receptors, CCR8 , Receptors, Virus/chemistry , Receptors, Virus/genetics , Receptors, Virus/immunology , Receptors, Virus/metabolism , Recombination, Genetic , Signal Transduction , Vaccinia/pathology , Vaccinia/virology , Vaccinia virus/genetics , Vaccinia virus/pathogenicity , Virion/metabolism , Virulence , Yatapoxvirus/genetics , Yatapoxvirus/metabolism
13.
J Virol Methods ; 130(1-2): 149-53, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16054706

ABSTRACT

The yatapoxvirus genus contains three members: tanapox virus (TPV), yaba-like disease virus (YLDV) and yaba monkey tumor virus (YMTV), two of which (TPV and YLDV) may infect humans. However, only a very small number of patients have been diagnosed with TPV outside Africa. Given the increased international travel and the similarity of clinical signs during the early stages of a TPV/YLDV infection as compared to diseases caused by agents of potential biological warfare, such as smallpox, monkeypox, tularemia and anthrax, the rapid and reliable recognition of a TPV/YLDV infection is crucial. A real-time PCR assay using TaqManchemistry was developed in order to identify unambiguously TPV/YLDV. Primers and probe targeting a 101bp region of the PstI L fragment of TPV, initial optimisations steps were carried out with YLDV DNA as template. Using probit regression analysis, the lower limit of detection was calculated to be ca. 8 copies per assay. A total of five TPV strains, one YDLV strain and scab-derived DNA from a patient with a TPV infection yielded specific amplification, whereas the DNA of YMTV was not amplified. Various viral and bacterial pathogens (n=29) associated with rash-causing illnesses were not detected using this assay.


Subject(s)
Polymerase Chain Reaction/methods , Poxviridae Infections/diagnosis , Tumor Virus Infections/diagnosis , Yaba monkey tumor virus/isolation & purification , Yatapoxvirus/isolation & purification , DNA Primers , Humans , Templates, Genetic , Yaba monkey tumor virus/genetics , Yatapoxvirus/genetics
14.
Proc Natl Acad Sci U S A ; 101(40): 14367-72, 2004 Oct 05.
Article in English | MEDLINE | ID: mdl-15448208

ABSTRACT

A conserved feature of poxviruses is a protein, well characterized as E3L in vaccinia virus, that confers IFN resistance on the virus. This protein comprises two domains, an N-terminal Z-DNA-binding protein domain (Zalpha) and a C-terminal double-stranded RNA-binding domain. Both are required for pathogenicity of vaccinia virus in mice infected by intracranial injection. Here, we describe the crystal structure of the Zalpha domain from the E3L-like protein of Yaba-like disease virus, a Yatapoxvirus, in a complex with Z-DNA, solved at a 2.0-A resolution. The DNA contacting surface of Yaba-like disease virus Zalpha(E3L) closely resembles that of other structurally defined members of the Zalpha family, although some variability exists in the beta-hairpin region. In contrast to the Z-DNA-contacting surface, the nonbinding surface of members of the Zalpha family are unrelated; this surface may effect protein-specific interactions. The presence of the conserved and tailored Z-DNA-binding surface, which interacts specifically with the zigzag backbone and syn base diagnostic of the Z-form, reinforces the importance to poxvirus infection of the ability of this protein to recognize the Z-conformation.


Subject(s)
DNA, Viral/chemistry , DNA, Z-Form/chemistry , Viral Proteins/chemistry , Yatapoxvirus/chemistry , Amino Acid Sequence , Base Sequence , Binding Sites , Crystallography, X-Ray , DNA, Viral/genetics , DNA, Z-Form/genetics , Macromolecular Substances , Models, Molecular , Molecular Sequence Data , Nucleic Acid Conformation , Protein Structure, Tertiary , Sequence Homology, Amino Acid , Static Electricity , Viral Proteins/genetics , Yatapoxvirus/genetics
15.
Proc Natl Acad Sci U S A ; 100(8): 4831-6, 2003 Apr 15.
Article in English | MEDLINE | ID: mdl-12676996

ABSTRACT

A class of secreted poxvirus tumor necrosis factor (TNF)-binding proteins has been isolated from Tanapox-infected cell supernatants. The inhibitor bound to a TNF-affinity column and was identified as the product of the 2L gene. Sequence analysis of 2L family members from other yatapoxviruses and swinepox virus yielded no sequence homology to any known cellular gene. The expressed Tanapox virus 2L protein bound to human TNF with high affinity (K(d) = 43 pM) and exhibits an unusually slow off-rate. However, 2L is unable to bind to a wide range of human TNF family members. The 2L protein can inhibit human TNF from binding to TNF receptors I and II as well as block TNF-induced cytolysis. Thus, Tanapox virus 2L represents an inhibitor of human TNF and offers a unique strategy with which to modulate TNF activity.


Subject(s)
Carrier Proteins/physiology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Viral Proteins/physiology , Yatapoxvirus/physiology , Amino Acid Sequence , Animals , Antigens, CD/metabolism , Base Sequence , Carrier Proteins/genetics , Carrier Proteins/pharmacology , DNA, Viral/genetics , Genes, Viral , Humans , Mice , Molecular Sequence Data , Receptors, Tumor Necrosis Factor/metabolism , Receptors, Tumor Necrosis Factor, Type I , Receptors, Tumor Necrosis Factor, Type II , Recombinant Proteins/genetics , Recombinant Proteins/pharmacology , Sequence Homology, Amino Acid , Tumor Necrosis Factor Decoy Receptors , Tumor Necrosis Factor-alpha/metabolism , Viral Proteins/genetics , Viral Proteins/pharmacology , Yaba monkey tumor virus/genetics , Yaba monkey tumor virus/physiology , Yatapoxvirus/genetics
16.
Virology ; 281(2): 170-92, 2001 Mar 15.
Article in English | MEDLINE | ID: mdl-11277691

ABSTRACT

The genome sequence of Yaba-like disease virus (YLDV), an unclassified member of the yatapoxvirus genus, has been determined. Excluding the terminal hairpin loops, the YLDV genome is 144,575 bp in length and contains inverted terminal repeats (ITRs) of 1883 bp. Within 20 nucleotides of the termini, there is a sequence that is conserved in other poxviruses and is required for the resolution of concatemeric replicative DNA intermediates. The nucleotide composition of the genome is 73% A+T, but the ITRs are only 63% A+T. The genome contains 151 tightly packed open reading frames (ORFs) that either are > or =180 nucleotides in length or are conserved in other poxviruses. ORFs within 23 kb of each end are transcribed toward the termini, whereas ORFs within the central region of the genome are encoded on either DNA strand. In the central region ORFs have a conserved position, orientation, and sequence compared with vaccinia virus ORFs and encode many enzymes, transcription factors, or structural proteins. In contrast, ORFs near the termini are more divergent and in seven cases are without counterparts in other poxviruses. The YLDV genome encodes several predicted immunomodulators; examples include two proteins with similarity to CC chemokine receptors and predicted secreted proteins with similarity to MHC class I antigen, OX-2, interleukin-10/mda-7, poxvirus growth factor, serpins, and a type I interferon-binding protein. Phylogenic analyses indicated that YLDV is very closely related to yaba monkey tumor virus, but outside the yatapoxvirus genus YLDV is more closely related to swinepox virus and leporipoxviruses than to other chordopoxvirus genera.


Subject(s)
Genome, Viral , Yaba monkey tumor virus/genetics , Yatapoxvirus/genetics , Adjuvants, Immunologic/genetics , Amino Acid Sequence , Animals , Cloning, Molecular , Genes, Regulator , Molecular Sequence Data , Open Reading Frames , Phylogeny , Sequence Alignment , Terminal Repeat Sequences , Viral Proteins/genetics , Yaba monkey tumor virus/classification , Yatapoxvirus/classification
SELECTION OF CITATIONS
SEARCH DETAIL
...